Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
Study Identifier:
2003141
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: pexelizumab in conjunction with CABG
Date
Jul 2004 - Oct 2005
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: pexelizumab in conjunction with CABG
Date
Jul 2004 - Oct 2005
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
During a heart bypass procedure, a substance called "complement" is activated by the body. This "complement activation" causes an inflammatory response that can lead to side affects such as chest pain, heart attacks, stroke, heart failure, or death. The purpose of this study is to find out if the study drug (pexelizumab), that blocks "complement activation," can reduce such side effects and be given safely to patients requiring the bypass procedure with the use of the heart-lung machine.
Trial Locations
Location
Status
Location
Brookwood Medical Center
Birmingham, Alabama, United States, 35209
Status
N/A
Location
Baptist Medical Center Princeton
Birmingham, Alabama, United States, 35211
Status
N/A
Location
Baptist Health Systems Montclair
Birmingham, Alabama, United States, 35213
Status
N/A
Location
Medical Center East Hospital
Birmingham, Alabama, United States, 35235
Status
N/A
Location
University of Alabama at Birmingham Hospital
Birmingham, Alabama, United States, 35249-6810
Status
N/A
Location
Thomas Hospital
Fairhope, Alabama, United States, 36532
Status
N/A